Description
RyonGraf.com is the personal website of Ryon Graf, who began a Cancer Q&A blog in February of 2011. Ryon is a researcher with interests in tumor metastasis, cancer therapy (resistance) and molecular evolution. Beyond the bench his interests in include intellectual property, scientific literacy, science policy, and bioethics, and these topics are also reflected in his blog as of 2012. "Cancer for Dummies" can also be found on Facebook: http://www.facebook.com/cancer.for.dummies
RyonGraf.com's Latest Posts
+
15 May 2013
This past year I’ve intently followed developments in personalized medicine, especially cancer, as technological advances in information gathering (DNA sequencing) grossly outpaces our ability to interpret such information. Also outpaced is the rate at which our ethical considerations can evolve and adapt to scenarios yielded by this rapidly changing intersection of information, [...]
+
22 April 2013
Today I came across a very interesting case-control study by Kumar et al. on the effects of metformin on the outcomes of ovarian cancer patients.
This study piqued my interest for a couple reasons. Metformin is already used in the clinic, is widely available, inexpensive, and its side effects are well-documented. [...]
+
7 April 2013
Good morning, dear readers. I was in lab sipping coffee and updating notebooks this calm Sunday morning when I stumbled across this beautifully clear, enlightening, and inspiring, if not haunting, glimpse into the consciousness of author Susan Gubar, currently battling ovarian cancer:
NT Times: Living With Cancer: Truthiness
Reading it coalesced [...]
+
2 April 2013
What happens when it’s impossible to tell where the cancer came from?
This morning I attended a great discussion at a bi-weekly meeting known as: Tumor Board. Oncologists will present difficult or interesting / unusual cases of patients they are seeing: diagnoses, observations, treatments, caveats with various forms of new [...]
+
A new generation of anti-caner therapies are truly marvels of science and engineering, with a hefty price tag.
As reported today by the New York Times, a new anti-breast cancer drug was approved today by the United States FDA. T-DM1 (Kadcyla) is a monoclonal antibody (Herceptin) attached to a toxic payload of mertansine [...]
Tags
